US OPEN: Wall Street opens flat after yesterday's carnage

2:42 PM 25 July 2024
  • Wall Street indices open more or less flat
  • US500 tests 50-session moving average
  • Viking Therapeutics surges 17% after Q2 earnings
  • Edward Lifesciences slumps 25% after Q2 earnings

Wall Street indices launched today's cash session more or less flat compared to yesterday's closing levels. S&P 500, Dow Jones and Nasdaq opened 0.05-0.10% higher, while small-cap Russell 2000 added 0.3% at session launch. This comes after yesterday's steep sell-off triggered by disappointing earnings releases from Alphabet and Tesla.

US GDP report released earlier today turned out to be a positive surprise, with annualized growth accelerating from 1.4% in Q1 2024 to 2.8% in Q2 2024, while analysts expected an acceleration to 2.0%. While the report triggered an uptick on US index futures, it was not enough to trigger a large move. Traders are weighing solid data from the US economy against risk of smaller or slower easing from Fed.

Start investing today or test a free demo

Open real account TRY DEMO Download mobile app Download mobile app

Source: xStation5

Wall Street indices are not allowed to catch a breath after yesterday's sell-off, with major US benchmarks failing to launch a recovery move. Taking a look at S&P 500 futures chart (US500) at D1 interval, we can see the index trade lower today, but the magnitude of the move is nowhere near that from yesterday. Index is making a break below the 50-session moving average (green line) today. However, according to Overbalance methodology, as long as the price stays above 5,350 pts area, where the lower limit of market geometry and 23.6% retracement can be found, the main trend remains bullish.

Company News

Viking Therapeutics (VKTX.US) launched today's cash session with a big bullish price gap, following release of Q2 earnings report. Company reported a $0.20 loss per share, less than $0.27 loss expected by analysts and slightly more than $0.19 loss reported a year ago. Drug developer is still in early-stage and continues to report $0 quarterly revenue. However, company said that its weight-loss drug advanced to late-stage trials and it is driving a spike in Viking's share price.

ServiceNow (NOW.US) jumped at the launch of today's cash trading, responding to Q2 earnings release. Company reported adjusted revenue at $2.64 billion (exp. $2.61 billion), with subscription revenue reaching $2.54 billion (exp. $2.53 billion). Adjusted gross profit of $2.17 billion also turned out to be higher than $2.15 billion expected. Remaining performance obligation was reported at $18.6 billion (exp. $17.6 billion), while current performance obligation was reported at $8.78 billion (exp. $8.68 billion). Company expects Q3 subscription revenue at $2.66-2.67 billion (exp. $2.68), while full-year forecast calls for 2024 subscription revenue of $10.58-10.59 billion, up from previous guidance of $10.56-10.58 billion.

Viking Therapeutics (VKTX.US) launched today's trading with a big bullish price gap. Stock rallies after Q2 earnings releases and is trading around 17% higher on the day. Bulls are now testing $60 resistance zone. Source: xStation5

West Pharmaceutical Services (WST.US) takes a hit after cutting full-year forecasts. Company reported 6.9% YoY drop in Q2 net sales to $702.1 million (exp. $729.3 million), with Proprietary Products net sales dropping 9.4% YoY to $559.7 million (exp. $592.8 million). Organic sales were 5.9% YoY lower. Adjusted operating income plunged 32% YoY to $126.4 million (exp. $155.1 million) and adjusted EPS was reported at $1.52, lower than $1.74 expected and $2.11 reported a year ago. Company lowered full-year net sales forecast from $3.00-3.03 billion to $2.87-2.90 billion) and adjusted EPS forecast from $7.63-7.88 to $6.35-6.65.

Edwards Lifesciences (EW.US) slumped after reporting a big miss in Q2 revenue. Company reported 9.4% YoY drop in revenue to $1.39 billion (exp. $1.65 billion). However, gross margin unexpectedly improved from 77.6% a year ago to 79.4% now (exp. 76.6%). Adjusted EPS of $0.70 also turned out to be higher than $0.66 reported a year ago and $0.69 expected by analysts for this quarter. Company expects Q3 sales to reach $1.56-1.64 billion (exp. $1.62 billion) while Q3 adjusted EPS is seen at $0.67-0.71 (exp. $0.69).

Edwards Lifesciences (EW.US) slumped after big Q2 sales miss. Company launched today's trading around 25% lower and trades at the lowest levels since November 2023. Source: xStation5

Share:
Back
Xtb logo

Join over 1 000 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits

We use cookies

By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

This group contains cookies that are necessary for our websites to work. They take part in functionalities like language preferences, traffic distribution or keeping user session. They cannot be disabled.

Cookie name
Description
SERVERID
userBranchSymbol cc 2 March 2024
test_cookie cc 25 January 2024
adobe_unique_id cc 1 March 2025
__hssc cc 8 September 2022
SESSID cc 2 March 2024
__cf_bm cc 8 September 2022
intercom-id-iojaybix cc 26 November 2024
intercom-session-iojaybix cc 8 March 2024

We use tools that let us analyze the usage of our page. Such data lets us improve the user experience of our web service.

Cookie name
Description
_gid cc 9 September 2022
_gat_UA-98728395-1 cc 8 September 2022
_gat_UA-121192761-1 cc 8 September 2022
_gcl_au cc 30 May 2024
_ga_CBPL72L2EC cc 1 March 2026
_ga cc 1 March 2026
__hstc cc 7 March 2023
__hssrc

This group of cookies is used to show you ads of topics that you are interested in. It also lets us monitor our marketing activities, it helps to measure the performance of our ads.

Cookie name
Description
MUID cc 26 March 2025
_omappvp cc 11 February 2035
_omappvs cc 1 March 2024
_uetsid cc 2 March 2024
_uetvid cc 26 March 2025
_fbp cc 30 May 2024
fr cc 7 December 2022
_ttp cc 26 March 2025
_tt_enable_cookie cc 26 March 2025
_ttp cc 26 March 2025
hubspotutk cc 7 March 2023

Cookies from this group store your preferences you gave while using the site, so that they will already be here when you visit the page after some time.

Cookie name
Description

This page uses cookies. Cookies are files stored in your browser and are used by most websites to help personalise your web experience. For more information see our Privacy Policy You can manage cookies by clicking "Settings". If you agree to our use of cookies, click "Accept all".

Change region and language
Country of residence
Language